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Introduction {#sec1}
============

Phosphoinositide 3-kinase (PI3K) is a central B cell receptor (BCR)-associated signaling axis that regulates diverse functions in developing B cells. Following BCR engagement ([@bib9], [@bib10]), PI3K catalyzes the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP~2~) to phosphatidylinositol-3,4,5-trisphosphate (PIP~3~) at the plasma membrane. Bruton's tyrosine kinase (Btk), phospholipase-γ2 (PLC-γ2), and the serine/threonine kinase Akt/PKB are among proteins containing pleckstrin-homology (PH) domains, that are recruited to the plasma membrane after the generation of PIP~3~ ([@bib2], [@bib8]). The lipid phosphatase Pten (phosphatase and tensin homolog) counteracts PI3K activity and dephosphorylates PIP~3~ to PIP~2~ ([@bib20], [@bib21]). In early B cells, PI3K controls *immunoglobulin* (*Ig*) gene recombination, and later in development, PI3K signaling regulates the survival of mature cells and their fate upon activation by influencing their program of differentiation ([@bib29], [@bib40]). In line with this finding, enhanced PI3K activity blocks class-switch recombination (CSR) and activates the formation of plasma cells ([@bib29], [@bib44]). Since plasma cell differentiation is mediated by the transcriptional suppressor Blimp-1 ([@bib36], [@bib37]), these data suggest that deregulated PI3K activity results in Blimp-1 activation and subsequent differentiation into plasma cells. In fact, Pten-deficient B cells are prone to undergo differentiation into plasma cells that secrete antibodies of the IgM isotype, as shown by highly elevated serum concentrations of IgM and reduced levels of IgA and IgG ([@bib29], [@bib44]). Moreover, inactivation of Pten at later stages of B cell development leads to an increased population of CD5-positive B cells known as B-1a B cells, which express autoreactive BCR specificities. BCR activation is considered to be important for the development and maintenance of several non-Hodgkin lymphomas (NHLs) including chronic lymphocytic leukemia (CLL) ([@bib7], [@bib35], [@bib41]). The importance of BCR activation and the downstream PI3K pathway for the malignant transformation of B cells is further supported by the fact that inhibitors for Btk or PI3K show effective therapeutic responses ([@bib6], [@bib39]). However, mice with B-cell-specific inactivation of Pten show no development of B cell lymphomas unless an additional phosphatase, Ship-1, is inactivated ([@bib25]). Thus, an important question is why Pten deficiency as such is not sufficient for the development of lymphoproliferative disease despite the presence of B cells expressing autoreactive BCRs and possessing deregulated PI3K activity.

Here, we test the hypothesis that activated B cells are disposed to Blimp-1-mediated terminal differentiation at all stages of development and, therefore, constitutive BCR engagement is not sufficient for induction of uncontrolled B cell expansion.

Results {#sec2}
=======

Reduced BCR Expression and Altered B Cell Compartments in *Pten*-Deficient B Mice {#sec2.1}
---------------------------------------------------------------------------------

Our previous experiments showed that inactivating the gene encoding Pten in pro-B cells using mb1-cre results in defective *Ig* gene recombination and a severe block at the pro-B cell stage ([@bib1]). Spleens from *Pten*^*f/f*^ × mb1-cre mice exhibit only small follicles lacking IgM^+^ cells, while the follicles in the spleens of *Pten*^*f/f*^ × CD19-cre mice show an abnormal distribution of IgM^+^ cells compared with control mice ([Figure 1](#fig1){ref-type="fig"}A). More detailed analysis revealed that some peripheral B cells exist in *Pten*^*f/f*^ × mb1-cre mice and that, based on fluorescence-activated cell sorting (FACS) staining for markers such as CD21 and CD23, cells corresponding to marginal zone B cells (MZ.B; CD21^hi^/CD23^lo/−^) or follicular B cells (Fo.B; CD21^+^/CD23^+^) can be found in these mice ([Figure 1](#fig1){ref-type="fig"}B). Moreover, an increased population of CD21^lo^/CD23^−^ B cells was also detected in the spleens of *Pten*^*f/f*^ × mb1-cre mice ([Figure 1](#fig1){ref-type="fig"}B). This enlarged CD21^lo^/CD23^−^ population contains transitional B cells but also seems to consist of B-1a B cells, which are characterized by CD5 and CD43 expression ([Figure 1](#fig1){ref-type="fig"}B) ([@bib31]) and partial reactivity to phosphatidylcholine (PtC) ([Figure S1](#mmc1){ref-type="supplementary-material"}A) ([@bib24], [@bib46]). This is similar to the *Pten*^*f/f*^ × CD19-cre mice that were previously shown to possess increased numbers of B-1a B cells ([Figures 1](#fig1){ref-type="fig"}B and 1C) ([@bib44]). As compared to *Pten*^*f/f*^ × CD19-cre mice, however, the majority of peripheral B cells in *Pten*^*f/f*^ × mb1-cre mice showed reduced IgM expression and no IgD ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B), whereas IgD-positive cells were detected in *Pten*^*f/f*^ × CD19-cre mice ([Figure 1](#fig1){ref-type="fig"}B). This difference might be caused by the developmental stage at which *Pten* was deleted in the different mouse strains. Indeed, due to differential gene expression of CD19 and mb1, CD19-cre acts at later stages of B cell development than mb1-cre, which acts prior to *Ig* gene recombination. It is conceivable that in B cells derived from *Pten*^*f/f*^ × CD19-cre mice, *Pten* gene inactivation occurs after *Ig* gene recombination, and this might be the reason for the increased numbers of B cells in the spleens of *Pten*^*f/f*^ × CD19-cre mice compared with *Pten*^*f/f*^ × mb1-cre mice ([Figure 1](#fig1){ref-type="fig"}B-C). These data suggest that regulation of PI3K activity is required for early stages of B cell development and proper selection of B cells into distinct B cell populations. Combining autoreactive BCRs with *Pten* deficiency did not lead to abnormal expansion of any B cell subsets (data not shown), suggesting that autoreactive BCR specificity, together with constitutive activation of PI3K signaling, is not sufficient for uncontrolled proliferation of B cells.Figure 1Reduced BCR Expression and Altered B Cell Compartments in Pten-Deficient Mice(A) Immunohistochemistry staining of spleen sections from control, *Pten*^*f/f*^ × mb1-cre and *Pten*^*f/f*^ × CD19-cre mice for CD169 (green), Thy1.2 (red), and IgM (yellow) at 10× magnification. Shown pictures are representative of 2 mice per genotype.(B) Representative flow cytometric analysis of splenocytes from mice of the indicated genotypes for expression of BCR (IgM/IgD), CD23, and CD21. Histograms compare CD5 and CD43 expression in the different B cell subpopulations (pre-gated on CD19^+^ cells): follicular B cells (Fo.B; CD21^+^/CD23^+^, blue), marginal zone B cells (MZ.B; CD21^hi^/CD23^lo/−^, red), and CD21^lo^/CD23^−^ B cells (green). Representative data of at least 8 mice per genotype are shown. Numbers in dotplots and histograms indicate the percentages of positive cells in the respective gates.(C) Absolute cell numbers of total B cells (gray, left), Fo.B (blue), MZ.B (red), CD21^lo^/CD23^−^ (green), and B1-a B cells (white, right) in spleens from control (n = 25), *Pten*^*f/f*^ × mb1-cre (n = 8) and *Pten*^*f/f*^ × CD19-cre mice (n = 18). Central horizontal line in the box represents the median, the upper and lower boundaries of the box show the respective quartile, and whiskers indicate the range of individual data.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

B Cells from Pten-Deficient Mice Are Committed to Terminal Differentiation {#sec2.2}
--------------------------------------------------------------------------

In agreement with previous reports ([@bib29], [@bib44]), we found that loss of Pten function in B cells, and thus increased PI3K activity, promotes plasma cell differentiation ([Figure 2](#fig2){ref-type="fig"}A). Although the percentage of plasma cells was low, B cells from Pten-deficient mice exhibited prior to stimulation an enhanced basal activity of mTor (mammalian target of rapamycin) as measured by S6 phosphorylation, and elevated levels of the transcription factors Irf4 and Blimp-1 compared to wild-type (WT) cells ([Figures 2](#fig2){ref-type="fig"}B and 2C). Three days upon stimulation with lipopolysaccharide (LPS), these factors were further elevated, while inhibitory factors such as Irf8, Bcl6, and Bach2 showed only slight changes ([Figures 2](#fig2){ref-type="fig"}B, 2C, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D). Foxo1 expression was specifically downregulated in CD138^+^ B cells in control and Pten-deficient mice ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). These findings indicate that elevated PI3K activity leads to basal activation of mTor, Irf4, and Blimp-1, which initiates terminal differentiation of B cells.Figure 2B Cells from Pten-Deficient Mice Are Committed to Terminal Differentiation(A) Splenocytes from mice of the indicated genotypes were left untreated (n. t. = non-treated) or stimulated with 2.5 μg/mL LPS and analyzed after 3 and 5 days for B220 and CD138 expression by flow cytometry (pre-gated on CD19^+^ cells). Bar diagrams besides the representative FACS plots show quantification of CD138^+^ B cells in LPS- and non-treated splenocytes at days 3 (top) and 5 (bottom) post stimulation. *Pten*^*f/f*^ (n = 7), *Pten*^*f/f*^ × mb1-cre (n = 6) and *Pten*^*f/f*^ × CD19-cre mice (n = 5), mean ± SD. Statistical significance was calculated by using the two-tailed paired (n. t. versus LPS) and otherwise the two-tailed unpaired t test.(B) Intracellular flow cytometric analysis of pS6, Irf4, and Blimp-1 expression in splenocytes from [Figure 2](#fig2){ref-type="fig"}A at day 3. Numbers in the histogram plots indicate the percentages of positive cells. Data are representative of at least 2 mice per genotype.(C) Immunoblot analysis of Blimp-1, Irf4, pS6, Irf8, and Bach2 expression in splenocytes from [Figure 2](#fig2){ref-type="fig"}A at day 3. n. t. = non-treated; Gapdh served as loading control. Data are representative of at least 2 mice per genotype.(D) Fo.B (CD21^+^/CD23^+^, blue), MZ.B (CD21^hi^/CD23^lo/−^, red), and CD21^lo^/CD23^−^ B cells (green) from control (n = 11), *Pten*^*f/f*^ × mb1-cre (n = 5) and *Pten*^*f/f*^ × CD19-cre mice (n = 4) were FACS-purified (for the gating strategy and re-analysis, see [Figures S3](#mmc1){ref-type="supplementary-material"}A, S3B, and S3F) and expression levels of *Blimp-1* in the respective B cell populations were determined by quantitative reverse transcriptase (RT)-PCR. Results are shown as relative units (RU) normalized to levels measured in bone-marrow (BM)-derived pro-B cells (CD19^+^/B220^+^/IgM^−^/IgD^−^/CD25^−^), mean + SD.(E) Concentrations of IgM in the sera of *Pten*^*f/f*^ and *Pten*^*f/f*^ × mb1-cre mice were measured by α-IgM ELISA, (n = 29; mean ± SD) (left). Levels of autoreactive antibodies in the respective sera were determined by α-dsDNA-IgM ELISA (*Pten*^*f/f*^, n = 21; *Pten*^*f/f*^ × mb1-cre, n = 19; mean ± SD) (right).See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.

In fact, we detected an increased population of CD138^+^/B220^lo^ plasma cells specifically within the population of CD21^lo^/CD23^−^ B cells in the spleens of *Pten*^*f/f*^ × mb1-cre mice ([Figure S2](#mmc1){ref-type="supplementary-material"}A), suggesting that CD21^lo^/CD23^−^ cells are particularly prone to undergo terminal differentiation. To further investigate this, we stimulated sorted B cells from all three compartments (Fo.B CD21^+^/CD23^+^, MZ.B CD21^hi^/CD23^lo/−^, and CD21^lo^/CD23^−^ B cells) with LPS ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and observed that B cells originating from the CD21^lo^/CD23^−^ population readily differentiated into plasma cells. This behavior was most evident in B cells from *Pten*^*f/f*^ × CD19-cre mice ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Moreover, the CD21^lo^/CD23^−^ B cells, which are increased in *Pten*^*f/f*^ × mb1-cre and *Pten*^*f/f*^ × CD19-cre mice, express the highest levels of *Blimp-1* among the B cell populations ([Figure 2](#fig2){ref-type="fig"}D; for the gating strategy and re-analysis, see [Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). The increased *Blimp-1* expression suggested that B cells with increased PI3K activity develop into a specific compartment that is committed to terminal differentiation under normal conditions. Accordingly, developing B cells that interact with auto-antigen may induce BCR-dependent PI3K signaling and become selected into this compartment. Indeed, the sera of *Pten*^*f/f*^ × mb1-cre mice, despite having decreased B cell numbers and a slightly reduced concentration of IgM, contain increased amounts of autoreactive IgM ([Figure 2](#fig2){ref-type="fig"}E).

Together, our results suggest that Pten deficiency is associated with enhanced development of autoreactive B cells and elevated Blimp-1 activity, leading to increased terminal differentiation and secretion of autoreactive antibodies.

Increased Autoreactivity in *Prdm1*-Deficient B Cells {#sec2.3}
-----------------------------------------------------

To directly test the role of Blimp-1 in early B cell selection, we performed a comprehensive analysis of B cell development in *Prdm1*^*f/f*^ × mb1-cre mice. The early expression of mb1 in pro-B cells ensures efficient deletion of *Prdm1* at the earliest stages prior to VDJ recombination. The total number of B cells in the spleens of *Prdm1*^*f/f*^ × mb1-cre mice were comparable to control mice, as were the amounts of Fo.B (CD21^+^/CD23^+^) and MZ.B (CD21^hi^/CD23^lo/−^) cells ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S4](#mmc1){ref-type="supplementary-material"}A). However, the compartment of CD21^lo^/CD23^−^ B cells was significantly increased ([Figure S4](#mmc1){ref-type="supplementary-material"}A), and a distinct CD23^−^ population with intermediate CD21 expression ([Figure 3](#fig3){ref-type="fig"}A) was detected. Such a population was previously shown to contain CD5^+^ B cells and to correlate with the production of autoantibodies ([@bib27]). In fact, the ratio and total cell number of B-1a B cells were increased in the absence of Blimp-1 ([Figures 3](#fig3){ref-type="fig"}A, 3B, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). The increased CD5^+^ B cell population was also observed after inducible deletion of *Prdm1 in vivo* ([Figure S4](#mmc1){ref-type="supplementary-material"}D), suggesting that the absence of antibodies in the sera of *Prdm1*^*f/f*^ × mb1-cre mice is unlikely the main reason for the expansion of B-1 cells in these mice. This finding indicates that Blimp-1 deficiency is associated with defects in B cell selection, thereby leading to increased numbers of potentially autoreactive B cells, as B-1a B cells often express autoreactive BCRs. To further test this, we determined the fraction of PtC-reactive B cells, since PtC is a common autoantigen recognized by B-1a BCRs ([@bib24], [@bib46]). PtC-reactive B cells were significantly increased in *Prdm1*^*f/f*^ × mb1-cre mice compared to control mice ([Figures 3](#fig3){ref-type="fig"}A, [S4](#mmc1){ref-type="supplementary-material"}C, and S4E). To confirm that Blimp-1 deficiency leads to the development of autoreactive B cells, we tested the antibody that might potentially be secreted by Blimp-1-deficient B cells. To this end, we introduced Blimp-1 by retroviral transduction into splenic *Prdm1*^*f/f*^ × mb1-cre B cells and measured the concentration of secreted anti-dsDNA-IgM antibody in the supernatant after 7 days of stimulation with LPS to induce terminal differentiation ([Figure 3](#fig3){ref-type="fig"}C). Our results show that the supernatant of B cells derived from *Prdm1*^*f/f*^ × mb1-cre mice contains significantly higher anti-dsDNA-IgM antibodies than control supernatants ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Increased Autoreactivity in Blimp-1-Deficient B Cells(A) Splenocytes from *Prdm1*^*f/f*^ and *Prdm1*^*f/f*^ × mb1-cre mice were analyzed by flow cytometry for surface expression of the indicated markers and reactivity to phosphatidylcholine (PtC).(B) Absolute numbers of total B cells and B-1a B cells in spleens from *Prdm1*^*f/f*^ x mb1-cre mice compared to controls (n = 14, median ± quartile and range).(C) *In vitro* antibody secretion by mature splenic B cells from mice of the indicated genotypes after retroviral transduction with the empty vector (EV) or an expression vector encoding Blimp-1 was measured by α-IgM ELISA (n = 9, mean ± SD). Statistical significance was calculated using a two-tailed paired t test (between EV and Blimp-1) or a two-tailed unpaired t test (between *Prdm1*^*f/f*^ and *Prdm1*^*f/f*^ × mb1-cre).(D) The autoreactive capacity of antibody secreted *in vitro* by splenocytes from mice of the indicated genotypes was determined by α-dsDNA ELISA (n = 9, mean ± SD). IgM concentrations used in the α-dsDNA ELISA were calculated based on the results shown (C), assuming that Blimp-1-reconstituted *Prdm1*^*f/f*^ and *Prdm1*^*f/f*^ × mb1-cre cells show similar concentrations.(E) Representative analysis of BCR expression in *Rag2/λ5*-double-knockout (DKO) pro-B cells reconstituted with heavy and light chain of NIP-(B1-8, middle) and hen-egg-lysozyme (HEL)-specific (HH10, bottom) IgM BCR or EV (top), respectively.(F) *Rag2/λ5*-DKO expressing either B1-8 (blue) or HH10 (red) BCR were mixed with untransduced (BCR-deficient) *Rag2/λ5*-DKO cells at a 1:1 ratio. Intracellular Blimp-1 expression levels were measured in BCR^+^ and BCR^−^ populations (defined by intracellular Ig-μHC staining) following 38 hr of incubation with anti-BCR antibodies (0.5 μg/mL α-λ or α-κLC, respectively) or the cognate antigen (Ag; 50 ng/mL NIP(7)-BSA or soluble HEL, respectively).(G) Quantification of the MFI of Blimp-1 (in the cells from F) normalized to the respective unstimulated control (EV, n = 13; B1-8^+/−^, n = 6; HH10^+/−^, n = 13; mean ± SD). Statistical significance was calculated using a two-tailed paired t test.(H) Percentages of viable Ig-μHC^+^ (intracellular \[ic\]) cells following 38 hr of stimulation with an α-LC antibody or the cognate antigen (as described in F).(I) Quantification of percentages of viable ic Ig-μHC^+^ cells (cells from H) normalized to the respective unstimulated control (EV, n = 13; B1-8^+/−^, n = 6; HH10^+/−^, n = 13; mean ± SD). Statistical significance was calculated compared to non-treated samples using a two-tailed paired t test.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

This points toward an unexpected role of Blimp-1 in early B cell development. Accordingly, B cells that fail to remove an autoreactive BCR specificity undergo Blimp-1-induced premature terminal differentiation. To test this directly, we expressed the heavy (HC) and light chain (LC) of the hen-egg-lysozyme (HEL)-specific BCR (HH10) and the 4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten (NIP)-specific B1-8 BCR in *Rag2/λ5*-double knockout (DKO) pro-B cells ([Figure 3](#fig3){ref-type="fig"}E) and tested induction of Blimp-1 expression after incubation with the cognate antigen or anti-BCR antibodies. In fact, treatment with antigen (HEL for HH10 and NIP(7)-BSA for B1-8 BCR, respectively) or anti-LC antibody led to upregulation of Blimp-1 ([Figures 3](#fig3){ref-type="fig"}F and 3G), and BCR-expressing cells were lost after incubation with these stimuli ([Figures 3](#fig3){ref-type="fig"}H and 3I). To show that Blimp-1 induction leads to negative selection *in vitro*, we transduced the *Rag2/λ5*-DKO with a *Blimp-1*-IRES-GFP retroviral vector and analyzed cell survival by monitoring GFP expression. We found that the majority of Blimp-1-expressing cells were lost within 2 days of culture as compared to cells transduced with the empty vector (EV) ([Figure S4](#mmc1){ref-type="supplementary-material"}F). In summary, these results indicate that BCR engagement at early B cell developmental stages induces Blimp-1 expression and leads to premature differentiation, thereby preventing further development of autoreactive B cells.

These data suggest that defective Blimp-1 function leads to the development of autoreactive B cells and an increased compartment of B-1a B cells. However, Blimp-1 deficiency as such is not sufficient to induce uncontrolled proliferation of B cells.

Bcl2 Protects from Blimp-1-Mediated Cell Death {#sec2.4}
----------------------------------------------

Previous findings indicated that anti-apoptotic factors can rescue cells from Blimp-1-mediated cell death ([@bib14], [@bib18]). Since our data indicate a role of Blimp-1 in early B cell development, we further analyzed the expression levels of *Blimp-1* and *Bcl2* in pro-B, small pre-B, and immature B cells from control mice ([Figure 4](#fig4){ref-type="fig"}A; for the gating strategy and re-analysis, see [Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). In fact, *Blimp-1* expression is elevated in small-pre-B cells. This finding is further supported by published gene expression data showing that *Blimp-1* is upregulated at the fraction D of non-cycling pre-B cells ([Figure S4](#mmc1){ref-type="supplementary-material"}G) ([@bib3], [@bib11], [@bib30]). At this stage, B cells rearrange the *Ig LC* gene and undergo selection for BCR function. Although *Blimp-1* expression is low compared to plasma cells ([Figure 4](#fig4){ref-type="fig"}A; for the gating strategy and re-analysis, see [Figure S3](#mmc1){ref-type="supplementary-material"}E), the expression level is comparable to immature or mature Fo.B cells ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}G).Figure 4Bcl2 Protects from Blimp-1-Mediated Cell Death(A) Pro-B cells (CD19^+^/B220^+^/IgM^−^/IgD^−^CD25^−^, orange, n = 6), small pre-B cells (CD19^+^/B220^+^/IgM^−^/IgD^−^/CD25^+^, blue, n = 6), and immature B cells (CD19^+^/B220^+^/IgM^+^/IgD^−^/CD25^−^, green, n = 6) from control mice were FACS-purified (for the gating strategy and re-analysis, see [Figures S3](#mmc1){ref-type="supplementary-material"}C--S3E), and expression levels of *Bcl2* and *Blimp-1* in the respective populations are shown as RU to the levels measured in pro-B cells. Expression levels are shown in comparison to FACS-purified plasma cells (gray, n = 7), mean + SD.(B) Splenic Fo.B (CD21^+^/CD23^+^, blue), MZ.B (CD21^hi^/CD23^lo/−^, red), CD21^lo^/CD23^−^ B cells (green), and B1-a B cells (control only, n = 6, gray) from control (n = 11), *Pten*^*f/f*^ × mb1-cre (n = 3), *Pten*^*f/f*^ × CD19-cre (n = 4) and *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice (n = 4) were FACS-purified (for the gating strategy and re-analysis, see [Figures S3](#mmc1){ref-type="supplementary-material"}A, S3B, and S3E), and expression levels of *Bcl2* in the respective B cell populations were determined by quantitative RT-PCR. Results are shown as RU normalized to levels measured in bone-marrow-derived pro-B cells (mean + SD).(C) Representative flow cytometric analysis data from concomitant expression of Bcl2 and Blimp-1 (top) or the EV (bottom) in *Rag2/λ5*-DKO pro-B cells, respectively, measured at days 2, 4, and 6 after transduction.(D) Quantified percentages of viable GFP^+^ (Bcl2) and/or Berry^+^ (Blimp-1 or EV, respectively) cells in the respective quadrants from [Figure 6](#fig6){ref-type="fig"}C at days 4 and 6 were normalized to the percentages measured at day 2 after transduction (right panel, n = 12, mean ± SD). Statistical significance was calculated using a two-tailed paired t test.(E) Cell-cycle analysis in Blimp-1- and EV-transduced cells from [Figures 6](#fig6){ref-type="fig"}C and 6D.(F) Measurement of apoptosis by staining for Annexin V in Blimp-1- and EV-transduced cells from [Figures 6](#fig6){ref-type="fig"}C--6E in absence (top) and presence (bottom) of Bcl2.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Since later stages of development such as Fo.B cells or B-1a cells also express higher levels of *Bcl2* than early cells or CD21^lo^/CD23^−^ B cells ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}G; for the gating strategy and re-analysis, see [Figures S3](#mmc1){ref-type="supplementary-material"}A, S3B, and S3F), it is conceivable that the increased Bcl2 protects these cells from Blimp-1-mediated premature differentiation. Interestingly, the CD21^lo^/CD23^−^ population in *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice shows significantly higher *Bcl2* expression ([Figure 4](#fig4){ref-type="fig"}B).

To show that *Blimp-1* expression leads to cell death *in vitro* unless cells are protected by anti-apoptotic factors, we transduced *Rag2/λ5*-DKO concomitantly with retroviral expression vectors for Blimp-1 and Bcl2 and analyzed cell survival by monitoring the fluorescence of the respective reporter. We found that the majority of Blimp1-expressing cells were lost within a few days of culture compared to cells transduced with the empty vector ([Figures 4](#fig4){ref-type="fig"}C and 4D). Only cells that were transduced with both Bcl2 and Blimp-1 were protected from Blimp-1-mediated cell death ([Figures 4](#fig4){ref-type="fig"}C and 4D). Blimp-1-transduced cells showed reduced mTor activity ([Figure S4](#mmc1){ref-type="supplementary-material"}H) and an impaired cell cycle ([Figure 4](#fig4){ref-type="fig"}E) and were more prone to apoptosis compared to cells transduced with the empty vector ([Figure 4](#fig4){ref-type="fig"}F). In the presence of Bcl2, Blimp-1-transduced cells were protected from apoptosis induced by premature terminal differentiation ([Figure 4](#fig4){ref-type="fig"}F).

Together, these results suggest that Blimp-1 can be induced already at early stages of B cell development, thereby leading to cell death by premature activation of the terminal differentiation program, which can be blocked by concomitant expression of anti-apoptotic factors.

Premature Terminal Differentiation Prevents Uncontrolled Proliferation {#sec2.5}
----------------------------------------------------------------------

Since increased PI3K activity induces Blimp-1, it is conceivable that induction of Blimp-1 may prevent the proliferation or survival of B cells with constitutive BCR signaling. In fact, Pten-deficient B cells show a moderate increase of B-1a B cells but normally no tumor development despite sustained PI3K activation ([Figure S5](#mmc1){ref-type="supplementary-material"}A). To investigate how Blimp-1 induction in Pten-deficient B cells prevents B cell expansion, we performed a detailed analysis of the *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice. These mice show an increased B-1a B cell compartment already at 7 and splenomegaly at 15 weeks of age ([Figures S5](#mmc1){ref-type="supplementary-material"}A and [5](#fig5){ref-type="fig"}A). Besides the increased population of B-1a cells showing a B220^lo^/CD5^int/+^ phenotype, T cells (B220^−^/CD5^hi^) and conventional B-2 B cells (B220^+^/CD5^−^) can be detected in the spleens of *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice ([Figure 5](#fig5){ref-type="fig"}B). The phenotype of B-1a cells was confirmed by further analysis of the B220^lo^/CD5^int/+^ population revealing that these cells, similar to B-1a B cells, are CD19^+^/B220^lo^/CD5^+^/IgM^+^/IgD^lo^/CD23^−^/CD21^lo^ and partially reactive to PtC ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Moreover, their numbers are dramatically increased in all lymphoid organs of the *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice ([Figures 5](#fig5){ref-type="fig"}B--5F and [S5](#mmc1){ref-type="supplementary-material"}B; data not shown). Since the CD21^lo^/CD23^−^ B cell population contains the B1-a B cells, which show higher *Bcl2* expression and accumulate in *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice, this might also be the reason for the significant increase of *Bcl2* expression in this population and group of mice ([Figure 4](#fig4){ref-type="fig"}B). Spleen sections showed an increased population of B cells with high IgM expression in the follicles of the respective mice ([Figure 5](#fig5){ref-type="fig"}G). To assess whether this prominent population of B-1a cells represents a transformed population with a clonal BCR, we analyzed the V(D)J usage in the CD19^+^/CD5^+^ population of the *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre splenic B cells ([Figure S5](#mmc1){ref-type="supplementary-material"}D; [Table S7](#mmc1){ref-type="supplementary-material"}). However, we detected merely random combinations of gene segments, suggesting that this population consists of a multitude of individual B cells. Together, our results suggest that the induction of Blimp-1 is an important mechanism for the prevention of uncontrolled B cell activation and expansion under conditions of constitutive BCR signaling.Figure 5Premature Terminal Differentiation Prevents Uncontrolled Proliferation(A) Macroscopic appearance of spleens from control and *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice.(B--E) Freshly isolated cells from spleens (B), bone marrow (C), peripheral blood (D), and peritoneal cavities (E) of control and *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice were analyzed by flow cytometry for surface expression of the indicated markers. Representative data are shown from at least 10 individual mice sacrificed and analyzed at the age of 16--20 weeks.(F) Absolute numbers of CD19^+^ and B-1a B cells in spleens from *Pten*^*f/f*^ x *Prdm1*^*f/f*^ x CD19-cre (n = 19, median ± quartile and range) compared to the cell numbers of *Pten*^*f/f*^ x CD19-cre and control mice already shown in [Figure 1](#fig1){ref-type="fig"}C.(G) Immunohistochemistry staining of spleen sections from mice of the indicated genotypes for CD169 (green), Thy1.2 (red), and IgM (yellow).See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Reconstitution of Blimp-1 Activates Terminal Differentiation {#sec2.6}
------------------------------------------------------------

To confirm that the increased proliferation of *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre B cells is caused by defective terminal differentiation of activated B cells, we investigated plasma cell differentiation in *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre B cells. We found that splenic B cells from *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice were defective in plasma cell differentiation ([Figures 6](#fig6){ref-type="fig"}A and 6B) and showed an enhanced survival capacity upon stimulation with LPS *in vitro* ([Figure S6](#mmc1){ref-type="supplementary-material"}A). In line with the *in vivo* data, Blimp-1 deficiency resulted in extended survival of CD21^lo^/CD23^−^ B cells, but not CD21^+^/CD23^+^ Fo.B cells, *in vitro* ([Figures 6](#fig6){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}B).Figure 6Reconstitution of Blimp-1 Activates Terminal Differentiation(A) Splenocytes from mice of the indicated genotypes were stimulated with 2.5 μg/mL LPS and after 5 days analyzed for B220 and CD138 expression by flow cytometry.(B) IgM and total IgG levels in sera from *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre (n = 17), *Pten*^*f/f*^ × CD19-cre (n = 6), and control mice (n = 7) (mean ± SD).(C) Fo.B (CD21^+^/CD23^+^, top) and CD21^lo^/CD23^−^ (bottom) splenic B cells from mice of the indicated genotypes were FACS-purified and cultured *in vitro*. The percentages of viable cells were monitored over 3 days, assessed by the morphology and staining with viability dye, and normalized to the percentage of viable cells at day 0 (n = 4, mean + SD).(D) Analysis of CD138 expression in *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre splenocytes 3 days following reconstitution with either Blimp-1 or EV by retroviral transduction. Histograms compare CD138 expression in GFP^+^ (Blimp-1-reconstituted) and GFP^−^ bystander cells. Numbers in the histogram plots indicate the percentages of CD138^+^ cells.(E) Analysis of Bcl2 expression in cells described in [Figure 5](#fig5){ref-type="fig"}D. Histograms compare Bcl2 expression in GFP^+^ (Blimp-1-reconstituted) and GFP^−^ bystander cells.(F) Splenocytes from *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice were reconstituted either with EV or Blimp-1, and the percentages of GFP^+^ cells were measured at day 5 after transduction and normalized to the respective percentages measured 3 days after transduction (n = 4, mean ± SD).(G) Splenocytes from *Pten*^*f/f*^ × *Prdm1*^*f/f*^ and *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × mb1-cre mice were analyzed by flow cytometry for surface expression of the indicated markers. Data are representative of 2 individual mice sacrificed and analyzed at the age of 10 and 17 weeks.Data shown in (D) and (E) are representative of two independent experiments. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

As expected, when Blimp-1 expression was reconstituted by retroviral transduction, *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre B cells showed efficient plasma cell differentiation ([Figure 6](#fig6){ref-type="fig"}D). Interestingly, Blimp-1 expression resulted in downregulation of the pro-survival factor Bcl2 ([Figure 6](#fig6){ref-type="fig"}E) and respective cells were rapidly lost *in vitro* ([Figure 6](#fig6){ref-type="fig"}F).

While most B cells are BCR-negative in the spleens of *Pten*^*f/f*^×mb1-cre mice, the block was partially rescued in *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × mb1-cre mice, resulting in a large fraction of cells expressing IgM BCR ([Figures 6](#fig6){ref-type="fig"}G, [S6](#mmc1){ref-type="supplementary-material"}C, and S6D). This suggests that Blimp-1-mediated premature terminal differentiation results in the removal of the vast majority of BCR expressing Pten-deficient early B cells. Together, these data indicate that sustained BCR signaling and deregulated PI3K activity result in Blimp1-mediated terminal differentiation of B cells, thereby interfering with early B cell selection and expansion of peripheral B cells.

Transgenic *Bcl2* Causes Uncontrolled Expansion of Pten-Deficient Cells {#sec2.7}
-----------------------------------------------------------------------

The above findings suggest that constitutive BCR activation together with deregulated PI3K activity leads to Blimp-1-induced apoptosis, thereby preventing uncontrolled expansion of Pten-deficient B cells that express autoreactive BCR. To test whether ectopic overexpression of Bcl2 could protect Pten-deficient cells from Blimp-1-mediated cell death, we crossed *Pten*^*f/f*^ × CD19-cre mice on a *Bcl2*-transgenic background. The resulting *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ mice exhibit an extremely enlarged spleen and lymph nodes already at the age of 10 weeks as compared to age-matched *Pten*^*f/f*^ × CD19-cre or *Bcl2*^*tg*^ controls ([Figure 7](#fig7){ref-type="fig"}A; data not shown). These mice were analyzed before 16 weeks of age, where signs of leukemic disease become evident. We observed a dramatically increased compartment of total B cells (CD19^+^/B220^+^) in bone marrow, spleen, peritoneal cavity, peripheral blood, and lymph nodes ([Figure 7](#fig7){ref-type="fig"}A--7D; data not shown). Although the B-1a compartment is significantly increased ([Figure 7](#fig7){ref-type="fig"}B), the majority of expanded B cells did not exhibit a classical B-1a phenotype in the *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ mice ([Figure 7](#fig7){ref-type="fig"}D). In contrast to spleens from *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre mice, the majority of B cells in these mice lack CD5 and surface BCR expression ([Figure 7](#fig7){ref-type="fig"}D). We compared the state of *Pten* deletion in the IgM^−/lo^/IgD^−^ and IgM^+^/IgD^+^ B cell subsets and found that *Pten* was deleted to comparable extent in both populations ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Since all surface IgM^−/lo^/IgD^−^ B cells showed intracellular Ig-μHC expression ([Figure S7](#mmc1){ref-type="supplementary-material"}B), we assume that this population is composed of B cell precursors and plasma cells. In fact, we detected antibody secreting cells among the IgM^−/lo^/IgD^−^ population from *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ and *Pten*^*f/f*^ × *Bcl2*^*tg*^ mice ([Figure 7](#fig7){ref-type="fig"}E). In full agreement, analysis of serum Ig revealed that IgM is strongly elevated in these mice ([Figure 7](#fig7){ref-type="fig"}F) and that the population of CD138^+^/B220^lo^ plasma cells is enlarged in the spleens of *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ mice as compared to *Bcl2*^*tg*^ mice ([Figure 7](#fig7){ref-type="fig"}G). In addition, a considerable proportion of the IgM^−/lo^/IgD^−^ population lacked LC expression while expressing Ig-μHC, suggesting that pre-BCR expression is involved in the expansion of these cells ([Figure S7](#mmc1){ref-type="supplementary-material"}B).Figure 7Transgenic *Bcl2* Causes Uncontrolled Expansion of Pten-Deficient B Cells(A) Macroscopic appearance of spleens from *Pten*^*f/f*^ × CD19-cre, *Pten*^*f/f*^ × *Bcl2*^*tg*^, and *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ mice sacrificed at the age of 10 weeks.(B) Absolute numbers of CD19^+^ and B-1a B cells in *Pten*^*f/f*^ x CD19-cre x *Bcl2*^*tg*^ (n = 5) and *Pten*^*f/f*^ x *Bcl2*^*tg*^ (n = 5) compared to the *Pten*^*f/f*^ x CD19-cre and control mice already shown in [Figures 1](#fig1){ref-type="fig"}C and [5](#fig5){ref-type="fig"}F (median ± quartile and range).(C and D) Cells freshly isolated from spleens (C) and bone marrow (D) of *Pten*^*f/f*^ × CD19-cre, *Pten*^*f/f*^ × *Bcl2*^*tg*^, and *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ mice were analyzed by flow cytometry for surface expression of the indicated markers. Representative data are shown from at least 5 mice sacrificed and analyzed at the age of 10 weeks.(E) ELISpot assay for secretion of IgM and IgG, respectively. IgM^−/lo^/IgD^−^ splenic B cells derived from mice of the indicated genotypes were FACS-purified and their capacity to secrete antibody was analyzed in triplicate after 16--24 hr of incubation (top). Numbers of dots in the triplicates were quantified (bottom), mean ± SD.(F) IgM levels measured in sera from *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ (n = 9), *Pten*^*f/f*^ × *Bcl2*^*tg*^ (n = 7), *Pten*^*f/f*^ × CD19-cre (n = 5), and control mice (n = 3) (mean ± SD).(G) Splenocytes from *Pten*^*f/f*^ × CD19-cre, *Pten*^*f/f*^ × *Bcl2*^*tg*^, and *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ mice were analyzed by flow cytometry for surface expression of CD138 and B220 in the BCR^+^ (CD19^+^/B220^+^/IgM^+^/IgD^+^) and BCR^−/lo^ (CD19^+^/B220^+^/IgM^−/lo^/IgD^−^) population of B cells.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Taken together, our results suggest that deregulated PI3K by Pten deficiency leads to activation-induced cell death at multiple stages of development and that rescuing from apoptosis results in abnormal expansion of corresponding cells. Moreover, Blimp-1-mediated premature terminal differentiation is required to prevent the generation and expansion of autoreactive B cells.

Discussion {#sec3}
==========

PI3K activity regulates B cell differentiation and the fate of developing B cells. In fact, chronic PI3K activation by deletion of *Pten* in the early stages of B cell development results in severe block due to defective *Ig* gene rearrangement ([@bib1]), whereas deleting *Pten* at later stages leads to alterations in the peripheral B cell compartments, such as increased generation of B-1 B cells and accelerated plasma cell differentiation ([@bib29], [@bib44]), suggesting that the development of Fo.B cells is suppressed in the absence of Pten. Since B-1 B cells require increased signaling for their development, Pten deficiency might cause the outgrowth of B cells that are persistently activated by their autoreactive BCR specificities and eventually become B-1 B cells ([@bib5], [@bib13], [@bib15], [@bib28]).

However, persistent BCR activation and constitutive PI3K signaling through Pten deficiency are not sufficient for malignant transformation, as Pten deficiency interferes with B cell maturation, thereby promoting the program of terminal differentiation by activation of Blimp-1 expression. Most likely, the amount of anti-apoptotic factors, including Bcl2, determines the survival of Pten-deficient B cells, as Blimp-1 has been shown to suppress the expression of genes driving proliferation ([@bib36]) and to interfere with Bcl2 expression ([@bib14]). Therefore, we propose that induction of Blimp-1 prevents the expansion of activated B cells and that this occurs already at the early stages of development. In agreement with previous studies ([@bib33], [@bib37], [@bib38]), our data show that Blimp-1 deficiency results in changes in B-1a B cells and, unexpectedly, in increased development of autoreactive B cells.

Our study reports a role for Blimp-1 in negative selection of B lymphocytes, thereby pointing to an unexpected recapitulation of regulatory networks in B cell development. In accordance with previous studies ([@bib45]), LPS-induced plasma cell differentiation led to increased Blimp-1 expression and elevated S6 phosphorylation by mTor. However, overexpression of Blimp-1 by retroviral transduction in pro-B cells resulted in reduced pS6 levels, suggesting that the amount of Blimp-1 and the stage of development are important for the relationship between Blimp-1 expression and the regulation of mTor activity.

Importantly, the transcription factor Irf4, which is known to be crucial for *LC* gene recombination and to be required for plasma cell differentiation and CSR ([@bib16], [@bib17], [@bib23], [@bib26]), seems to be involved in the Blimp-1-mediated premature terminal differentiation. In analogy to available data ([@bib34]) showing that high Irf4 amounts induce Blimp-1 while intermediate levels of Irf4 induce AID, which is required for CSR, it is conceivable that intermediate levels of Irf4 at early stages of development activate Rag-mediated *LC* gene recombination while increased levels activate Blimp-1 that interferes with cell division and survival ([@bib36]). Thus, the induction of Blimp-1 in B cells that express autoreactive BCRs or harbor mutations, such as Pten deficiency, represents a safeguard mechanism that prevents the development of autoreactive B cells and interferes with proliferation ([@bib36]). In fact, our data show that Blimp-1 deficiency or combined deficiency of Pten and Blimp-1 leads to an increased proportion of autoreactive B cells and abnormal expansion of B-1a B cells, respectively. This suggests that Blimp-1 not only acts as tumor suppressor in B cells ([@bib4], [@bib19], [@bib22]) it is also required for proper selection of antibody repertoire. Therefore, elucidating the signaling pathways that activate Blimp-1 is not only required for understanding plasma cell differentiation and the suppression of malignant transformation but also for understanding the molecular mechanisms that regulate the selection of developing B cells.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

*Pten*^*f/f*^ (provided by T. Mak; Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, Toronto, ON, Canada; [@bib44]) and *Prdm1*^*f/f*^ ([@bib37]) mice were crossed either to mb1-cre (CD79a-cre) ([@bib12]) or CD19-cre ([@bib32]) transgenic mice for B-cell-specific cre-mediated recombination. *Pten*^*f/f*^ × CD19-cre mice were bred to either *Prdm1*^*f/f*^ or *Bcl2*-transgenic mice ([@bib43]) in order to generate *Pten*^*f/f*^ × *Prdm1*^*f/f*^ × CD19-cre or *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ mice, respectively. Male or female mice at 8 to 60 weeks of age were used in this study. Mice with WT, homozygous, or heterozygous floxed alleles for *Prdm1* or *Pten* were used as controls (*ctrl*).

Mice were bred and housed under specific-pathogen-free conditions in the animal facility of Ulm University. All animal experiments were done in compliance with the guidelines of the German law and approved by the Animal Care and Use Committees of Ulm University and the local government.

Cell Culture and Biochemistry {#sec4.2}
-----------------------------

Phoenix and mature splenic B cells were cultured in Iscove's medium (Biochrom AG) containing 10% heat-inactivated fetal calf serum (FCS; PAN-Biotech), 2 mM [l]{.smallcaps}-glutamine, 100 U/mL penicillin (Gibco), 100 U/mL streptomycin (Gibco), and 50 μM β-mercaptoethanol (Gibco). *Rag2/λ5*-deficient cell lines were established by culturing bone marrow cells from the respective mice ([@bib23], [@bib42]) in medium supplemented with the supernatant of J558L plasmacytoma cells stably transfected with a vector encoding murine IL-7. Cells were stimulated either with 0.5 μg/mL unlabeled α-kappa or α-lambda antibody (both polyclonal; Southern Biotech), 50 ng/mL soluble HEL (Sigma-Aldrich), or 50 ng/mL NIP(7)-BSA (Biosearch Technologies), respectively.

Plasmids and Retroviral Transduction {#sec4.3}
------------------------------------

Full-length cDNA encoding Blimp-1 or Bcl2, respectively, was subcloned into the retroviral vector backbone pMI to generate *Blimp-1*-IRES-Berry, *Blimp-1*-IRES-GFP, and *Bcl2*-IRES-GFP expression vectors. Immunoglobulin HCs and LCs were expressed by using the BiFC vector system as described ([@bib47]). Viral supernatants were generated using the Phoenix retroviral producer cell line as described in the manufacturer's instructions. Phoenix cells were cultured in Iscove's culture medium + 10% FCS. Cells were plated at a density of 10^6^ cells/mL to generate supernatants by using the transfection reagent GeneJuice (Merck Millipore). Retroviral supernatants were harvested after 48 hr. For the subsequent transduction, the respective cells were mixed with supernatants and centrifuged for 3 hr at 300 × *g* and 37°C. Transduced cells were cultured for 4--5 days and analyzed by flow cytometry.

Flow Cytometry {#sec4.4}
--------------

For flow cytometric analysis, cell suspensions were pretreated with α-CD16/CD32 Fc-Block (2,4G2; BD Biosciences) and stained by standard procedures. Dead cells were excluded by staining with Fixable Viability Dye eFluor 780 (eBioscience). Cells were stained using the antibodies listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

PtC-reactive cells were identified by staining with PtC-liposome fluorescein-DHPE (FormuMax Scientific). Biotin was detected by using Streptavidin Qdot 605 (Molecular Probes/Invitrogen). Unconjugated α-Pten- and α-Foxo1 antibodies were detected by using α-rabbit IgG (H+L) F(ab′)~2~ fragment-Alexa Fluor 647 (Cell Signaling). Intracellular flow cytometric staining was performed using the kits listed in [Table S2](#mmc1){ref-type="supplementary-material"} according to the manufacturer's instructions.

Cells were acquired at a FACSCantoII flow cytometer (BD Biosciences). If not indicated otherwise, numbers in the dot plots indicate the percentages of cells in the respective gates, numbers in the histograms indicate the mean fluorescence intensity (MFI).

Cell-Cycle and Apoptosis Analysis {#sec4.5}
---------------------------------

For cell-cycle analysis, cells were pulsed for 30 min with BrdU (APC BrdU Flow Kit; BD Biosciences) and stained according to instructions given by the manufacturer. Apoptosis was analyzed using Annexin V binding buffer (BD Biosciences) and staining with Annexin V-Alexa Fluor 647 (BioLegend).

Immunoblotting {#sec4.6}
--------------

Equal amounts of denatured protein were separated by SDS-gel electrophoresis on a 10% gel and transferred onto a PVDF membrane. The membrane was blocked for 1 hr with PBS-T (PBS/0.05% Tween; Sigma) containing 5% BSA (Serva) and washed before probing overnight with the primary antibody diluted in blocking solution. Antibodies used for immunoblotting are listed in [Table S3](#mmc1){ref-type="supplementary-material"}.

After washing steps, the membrane was incubated for 1 hr at room temperature (RT) with horseradish peroxidase (HRP)-coupled secondary goat α-rabbit antibodies diluted in PBS-T/1% BSA. Antibody in excess was washed off, and stained proteins were detected with ECL Ultra Solution kit (Lumigen) on a Fusion SL advanced imaging system (Vilber Lourmat).

Immunohistochemistry {#sec4.7}
--------------------

For cryosections, spleens were embedded in OCT-compound (Sakura) and frozen at −80°C. 5-μm sections were prepared using a cryo-microtome (Reichert-Jung 2800 Frigocut) with a S35 knife (Feather) and fixed on SuperfrostPLUS slides (Thermo Scientific) by treatment with pure acetone. Prior to staining the sections were rehydrated with PBS + 2% BSA + 0.1% Na-azide and blocked with Fc-Block (α-CD16/32; BD Biosciences). Sections were stained with the antibodies listed in [Table S4](#mmc1){ref-type="supplementary-material"}. The section was mounted with Fluoromount-G (Southern Biotech). Staining was detected using an Axioskop2 fluorescence microscope (Zeiss, Oberkochen, Germany).

Enzyme-Linked Immunoblot Assay {#sec4.8}
------------------------------

Mature splenic B cells from the indicated genotypes were cultured in the presence of 2.5 μg/mL LPS from *Escherichia coli* (0111:B4; Sigma-Aldrich) for 1.5 days and subjected to retroviral transduction either with pMIG (EV) or pMIG-*Blimp-1*, respectively. The supernatants were collected 5 days after transduction and used for α-IgM and α-dsDNA-IgM-ELISA.

For the α-IgM and α-IgG ELISAs 96-well plates (NUNC, maxisorp) were coated with polyclonal α-mouse IgM or IgG antibody (SouthernBiotech) and blocked with buffer containing 1% BSA. Dilutions of α-mouse IgM/IgG (SouthernBiotech) were used as standard. The concentration of IgM and IgG in the supernatants was determined by detection with alkaline-phosphatase-labeled α-mouse IgM or IgG (Southern Biotech), respectively. P-nitrophenylphosphate (Genaxxon) in diethylamine buffer was added and data were acquired at 405 nm using a Multiskan FC ELISA plate reader (Thermo Scientific). To determine the content of autoreactive IgM antibodies, IgM-concentration-adjusted cell culture supernatants were applied to plates coated with calf thymus DNA (Rockland Immunochemicals). The detection and development was performed as described for the α-IgM ELISA.

ELISpot Assay {#sec4.9}
-------------

CD19^+^/B220^+^/IgM^−/lo^/IgD^−^ were FACS-purified from the spleens of *Pten*^*f/f*^ × CD19-cre × *Bcl2*^*tg*^ or *Pten*^*f/f*^ × *Bcl2*^*tg*^ mice, respectively. 5--10 × 10^4^ cells per well were plated in triplicates. The assay was performed for IgM and IgG (Mabtech ELISpot Basic \[ALP\]) according to the manufacturer's instructions.

Quantitative RT-PCR {#sec4.10}
-------------------

Cells were purified using a FACSAria IIu sorter (BD Biosciences). RNA was extracted from FACS-sorted cells by using the ReliaPrep RNA Cell Miniprep System (Promega) and cDNA synthesis was performed with the RevertAid Reverse Transcriptase kit (Thermo Fisher) as indicated by the manufacturer. qPCR analysis was performed in triplicate using TaqMan-Probe mixes (Applied Biosystems; listed in [Table S5](#mmc1){ref-type="supplementary-material"}) with TaqMan gene expression mastermix (Applied Biosystems). qRT-PCR data were acquired on a StepOnePlus Real-Time thermocycler (Applied Biosystems) and analyzed with the StepOne Software version 2.3. Results were calculated by applying the ΔΔCT-method.

Statistical Analysis {#sec4.11}
--------------------

Graphs were created and statistical analysis was performed using GraphPad Prism (version 6.0h) software. The numbers of individual replicates or mice (n) is stated in the figure legends or the figure itself. If not indicated otherwise p values were calculated by applying two-tailed unpaired t tests. p values \< 0.05 were considered to be statistically significant (n. s., not significant; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; ^∗∗∗∗^p \< 0.0001).
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